Fifty-one children with Mediterranean spotted fever (MSF) were randomized to receive either clarithromycin, 15 mg/kg/day orally in 2 divided doses, or chloramphenicol, 50 mg/kg/day orally in 4 divided doses, for 7 days. Mean time to defervescence was 36.7 h in the clarithromycin group and 47.1 h in the chloramphenicol group (P=.047). Clarithromycin could be an acceptable therapeutic alternative to chloramphenicol and to tetracyclines for children aged <8 years with MSF
Cascio, A., Colomba, C., Di Rosa, D., Salsa, L., di Martino, L., TITONE LANZA DI SCALEA, L. (2001). Efficacy and safety of clarithromycin as treatment for Mediterranean spotted fever in children: a randomized controlled trial. CLINICAL INFECTIOUS DISEASES, 33(3), 409-411.
Efficacy and safety of clarithromycin as treatment for Mediterranean spotted fever in children: a randomized controlled trial
CASCIO, ANTONIO;COLOMBA, Claudia;TITONE LANZA DI SCALEA, Lucina
2001-01-01
Abstract
Fifty-one children with Mediterranean spotted fever (MSF) were randomized to receive either clarithromycin, 15 mg/kg/day orally in 2 divided doses, or chloramphenicol, 50 mg/kg/day orally in 4 divided doses, for 7 days. Mean time to defervescence was 36.7 h in the clarithromycin group and 47.1 h in the chloramphenicol group (P=.047). Clarithromycin could be an acceptable therapeutic alternative to chloramphenicol and to tetracyclines for children aged <8 years with MSF
| File | Dimensione | Formato | |
|---|---|---|---|
|
Efficacy and Safety of Clarithromycin.pdf
accesso aperto
Dimensione
65.99 kB
Formato
Adobe PDF
|
65.99 kB | Adobe PDF | Visualizza/Apri |
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
